General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-06-06 | 2024-03 | 0 | N/A | N/A | N/A |
2024-03-28 | 2023-12 | -0.27 | -0.31 | -0.04 | -14.81% |
2023-11-30 | 2023-09 | -0.43 | -0.43 | N/A | N/A |
2023-08-31 | 2023-06 | -0.54 | -0.4 | 0.14 | 25.93% |
2023-06-01 | 2023-03 | 0 | -0.65 | N/A | N/A |
2023-03-30 | 2022-12 | -0.57 | -1.11 | -0.54 | -94.74% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-06-01 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-12 | HC Wainwright & Co. | Upgrade | Buy |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Morgan Stanley | 33.31K | 102.25K | 2.16% |
2023-06-29 | Rhumbline Advisers | 17.10K | 52.50K | 1.11% |
2023-06-29 | Fifth Third Bancorp | 3.00K | 9.21K | 0.19% |
2023-06-29 | Citigroup Inc. | 553.00 | 1.70K | 0.04% |
2023-09-29 | National Bank of Canada/FI | 600.00 | 1.59K | 0.04% |
Split | Date |
---|---|
1 : 10 | 2023-01-09 |
1 : 15 | 2019-05-10 |
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
Results to be shared at Biotech Showcase during JP Morgan conference week in San Francisco and at BI0-CEO in New York
An advanced CPB liver cancer patient remains clear of cancer 6 years following treatment with Namodenoson
While CPB patients are typically excluded from liver cancer clinical studies due to low expected response rates, Namodenoson-treated CPB7 patients had statistically significant overall survival gain
Few more weeks to get approved by FDA ! Phase lll is done
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
Mentioned: CANF
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2022.
Corporate and Clinical Development Highlights Include:
Strong Balance Sheet - On June 30, 2022, Can-Fite had approximately $12.72 million in cash, cash equivalents, and short-term deposits.
Namodenoson Approved for Compassionate Use in Romania, Pivotal Phase III Liver Cancer Study Open for Enrollment - In August, Can-Fite announced Romania became the second country, following Israel, to approve Namodenoson for compassionate use in patients with advanced liver cancer. Namodenoson induced a complete response with disappearance of all metastases in a Romanian patient who was enrolled in Can-Fite's prior Phase IIb liver cancer study, and the patient will now continue treatment under the compassionate use program. Can-Fite's pivotal Phase III liver cancer study for Namodenoson is open for enrollment of approximately 450 patients diagnosed with hepatocellular carcinoma (HCC) and underlying Child Pugh B7 (CPB7) who have not responded to other approved therapies.
Phase III COMFORT(TM) Trial for Psoriasis Meets Primary Endpoint - Topline results were announced during the second quarter, and further data are expected in the coming weeks. Piclidenoson, Can-Fite's lead drug candidate, successfully met its primary endpoint in the Phase III COMFORT trial in more than 400 adults with moderate to severe plaque psoriasis. At week 16, patients receiving Piclidenoson 3mg demonstrated statistically significant improvement when compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response (representing a 75% reduction in psoriasis severity): Piclidenoson 3mg: 9.7% vs. placebo: 2.6% (P< 0.04). A linear increase in the response of patients to Piclidenoson was achieved along the study period, on week 48 reaching a PASI 50 response (50% reduction in psoriasis severity) in 90% of patients, a PASI 90 response (90% reduction in psoriasis severity) in 10% of patients, and Psoriasis Disability Index (PDI) improvement in 60% of patients.
Company to Submit FDA & EMA Registration Plans for Piclidenoson for the Treatment Psoriasis - Following the successful COMFORT study, Can-Fite is planning to submit its marketing registration plans to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for Piclidenoson in the treatment of moderate to severe psoriasis. The pivotal Phase III study's protocol is being developed in conjunction with Dr. Kim Papp, a Key Opinion Leader in dermatology and an investigator in the COMFORT study. Current chemistry, manufacturing, and controls (CMC), nonclinical data, and human pharmacokinetic data will be submitted to the FDA and EMA along with the pivotal Phase III protocol and other supporting clinical pharmacology plans.
Data show Piclidenoson's Superior Safety Profile and Higher Patient Compliance Compared to Otezla(R) - In July, Can-Fite announced that further analysis of the Phase III COMFORT data point toward a better safety profile for Piclidenoson as compared to Otezla, which induced gastrointestinal adverse events in 6% of patients compared with 1% in patients treated with placebo or Piclidenoson. Discontinuation of treatment amongst patients treated with Otezla was significantly higher compared to that of the Piclidenoson treated patients.
Piclidenoson Demonstrates Higher Efficacy in Patients with More Severe Disease - Also announced in July a sub-analysis of the efficacy data that divided patients into those who had PASI>25 (more severe psoriasis) and PASI<25 (less severe) at baseline revealed that patients who started with higher PASI values at entry benefitted more from treatment with Piclidenoson as compared to placebo.
Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results
https://www.benzinga.com/general/biotech/22/07/28065784/industry-analysts-seemingly-sing-praises-for-this-stock-after-phase-iii-trial-results https://www.benzinga.com/general/biotech/22/07/28065784/industry-analysts-seemingly-sing-praises-for-this-stock-after-phase-iii-trial-results
Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results
https://www.benzinga.com/general/biotech/22/07/28065784/industry-analysts-seemingly-sing-praises-for-this-stock-after-phase-iii-trial-results https://www.benzinga.com/general/biotech/22/07/28065784/industry-analysts-seemingly-sing-praises-for-this-stock-after-phase-iii-trial-results
It’s good news. They now have topical and oral treatments for psoriasis
My mushroom tip is starting to tingle
My mushroom tip is starting to tingle
What a